Back in 2020, CRISPR Therapeutics (NASDAQ: CRSP) left the Dow Jones Industrial Average (DJIA) in the dust. The stock soared more than 150%, while the DJIA delivered a modest 7% increase. Investors were excited about biotech companies -- and CRISPR's gene-editing technology caught their attention.

But as economic woes accumulated over the past couple of years, investors fled stocks they perceived as risky. And CRISPR, with a newish technology that hadn't yet resulted in a commercialized product, fell out of favor.

The economic situation remains tumultuous right now. At the same time, CRISPR has a major catalyst ahead that could help it beat the Dow Jones this year and even over time. Let's take a closer look.

Continue reading

Source Fool.com